Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 8/20 | 0.44 |
| ▸ | AURKA | O14965 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6128887 | 1.00 | RPS6KB1 (0.44) | RPS6KB1AURKATP53LMNAPDPK1 | |
| SCHEMBL17545959 | 0.97 | TP53 (0.45) | RPS6KB1AURKATP53LMNAPDPK1 | |
| SCHEMBL10228636 | 0.94 | HTR6 (0.45) | RPS6KB1AURKATP53LMNABRD4 | |
| SCHEMBL6128796 | 0.94 | HTR6 (0.45) | RPS6KB1AURKATP53LMNABRD4 | |
| SCHEMBL10228229 | 0.90 | L3MBTL1 (0.43) | TP53LMNAMAOBHTR6ADORA3 | |
| SCHEMBL17583145 | 0.88 | TP53 (0.43) | RPS6KB1AURKATP53LMNAHTR6 | |
| SCHEMBL18419022 | 0.88 | TP53 (0.54) | TP53LMNAADORA3ADORA2AADORA1 | |
| SCHEMBL16764865 | 0.83 | TP53 (0.38) | TP53LMNAMAOBHTR6ADORA3 | |
| SCHEMBL31124371 | 0.82 | TP53 (0.43) | TP53LMNAADORA3ADORA2AADORA1 | |
| SCHEMBL17546629 | 0.82 | TP53 (0.42) | TP53LMNAHTR6ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | RPS6KB1 867/4885AURKA 69/4885TP53 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.